Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

NCT07689539 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: DN022150
DRUG: Chemotherapy

Sponsor

Jiangxi Kvvit Pharmaceutical Co., Ltd.